Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays

David M. Hyams; Eric Schuur; Javier Angel Aristizabal; Juan Enrique Bargallo Rocha; Cesar Cabello; Roberto Elizalde; Laura García-Estévez; Henry L. Gomez; Artur Katz; Aníbal Nuñez De Pierro

doi:10.1002/jso.24561

Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays

David M. Hyams
, Eric Schuur
, Javier Angel Aristizabal
, Juan Enrique Bargallo Rocha
, Cesar Cabello
, Roberto Elizalde
, Laura García-Estévez
, Henry L. Gomez
, Artur Katz
, Aníbal Nuñez De Pierro

Eisenhower Medical Center
VMWA LLC
National Institute of Cancer
National Cancer Institute
University of Campinas
Hospital Dr. Ignacio Pirovano
Centro Integral Oncológico Comprensivo Clara Campal
Instituto Nacional de Enfermedades Neoplásicas Eduardo Cáceres Graziani
Center of Check of Hospital Sirio Libanes
Hospital General de Agudos Juan A Fernández

Producción científica: Contribución a una revista › Artículo de revisión › revisión exhaustiva

18 Citas (Scopus)

Resumen

Risk stratification of patients with early stage breast cancer may support adjuvant chemotherapy decision-making. This review details the development and validation of six multi-gene classifiers, each of which claims to provide useful prognostic and possibly predictive information for early stage breast cancer patients. A careful assessment is presented of each test's analytical validity, clinical validity, and clinical utility, as well as the quality of evidence supporting its use.

Idioma original	Inglés
Páginas (desde-hasta)	647-662
Número de páginas	16
Publicación	Journal of Surgical Oncology
Volumen	115
N.º	6
DOI	https://doi.org/10.1002/jso.24561
Estado	Publicada - 1 may. 2017
Publicado de forma externa	Sí

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

ODS 3: Salud y bienestar

Acceder al documento

10.1002/jso.24561

Otros archivos y enlaces

Enlace a la publicación en Scopus

Citar esto

Hyams, D. M., Schuur, E., Angel Aristizabal, J., Bargallo Rocha, J. E., Cabello, C., Elizalde, R., García-Estévez, L., Gomez, H. L., Katz, A., & Nuñez De Pierro, A. (2017). Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays. Journal of Surgical Oncology, 115(6), 647-662. https://doi.org/10.1002/jso.24561

@article{e7c450e03d564d089e196a06b1022333,

title = "Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays",

abstract = "Risk stratification of patients with early stage breast cancer may support adjuvant chemotherapy decision-making. This review details the development and validation of six multi-gene classifiers, each of which claims to provide useful prognostic and possibly predictive information for early stage breast cancer patients. A careful assessment is presented of each test's analytical validity, clinical validity, and clinical utility, as well as the quality of evidence supporting its use.",

keywords = "adjuvant, biomarkers, breast neoplasms, chemotherapy, clinical decision-making, gene expression, genomics risk, prognosis, tumor",

author = "Hyams, \{David M.\} and Eric Schuur and \{Angel Aristizabal\}, Javier and \{Bargallo Rocha\}, \{Juan Enrique\} and Cesar Cabello and Roberto Elizalde and Laura Garc{\'i}a-Est{\'e}vez and Gomez, \{Henry L.\} and Artur Katz and \{Nu{\~n}ez De Pierro\}, An{\'i}bal",

note = "Publisher Copyright: {\textcopyright} 2017 The Authors. Journal of Surgical Oncology Published by Wiley Periodicals, Inc.",

year = "2017",

month = may,

day = "1",

doi = "10.1002/jso.24561",

language = "Ingl{\'e}s",

volume = "115",

pages = "647--662",

journal = "Journal of Surgical Oncology",

issn = "0022-4790",

number = "6",

}

Hyams, DM, Schuur, E, Angel Aristizabal, J, Bargallo Rocha, JE, Cabello, C, Elizalde, R, García-Estévez, L, Gomez, HL, Katz, A & Nuñez De Pierro, A 2017, 'Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays', Journal of Surgical Oncology, vol. 115, n.º 6, pp. 647-662. https://doi.org/10.1002/jso.24561

Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays. / Hyams, David M.; Schuur, Eric; Angel Aristizabal, Javier et al.
En: Journal of Surgical Oncology, Vol. 115, N.º 6, 01.05.2017, p. 647-662.

Producción científica: Contribución a una revista › Artículo de revisión › revisión exhaustiva

TY - JOUR

T1 - Selecting postoperative adjuvant systemic therapy for early stage breast cancer

T2 - A critical assessment of commercially available gene expression assays

AU - Hyams, David M.

AU - Schuur, Eric

AU - Angel Aristizabal, Javier

AU - Bargallo Rocha, Juan Enrique

AU - Cabello, Cesar

AU - Elizalde, Roberto

AU - García-Estévez, Laura

AU - Gomez, Henry L.

AU - Katz, Artur

AU - Nuñez De Pierro, Aníbal

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Risk stratification of patients with early stage breast cancer may support adjuvant chemotherapy decision-making. This review details the development and validation of six multi-gene classifiers, each of which claims to provide useful prognostic and possibly predictive information for early stage breast cancer patients. A careful assessment is presented of each test's analytical validity, clinical validity, and clinical utility, as well as the quality of evidence supporting its use.

AB - Risk stratification of patients with early stage breast cancer may support adjuvant chemotherapy decision-making. This review details the development and validation of six multi-gene classifiers, each of which claims to provide useful prognostic and possibly predictive information for early stage breast cancer patients. A careful assessment is presented of each test's analytical validity, clinical validity, and clinical utility, as well as the quality of evidence supporting its use.

KW - adjuvant

KW - biomarkers

KW - breast neoplasms

KW - chemotherapy

KW - clinical decision-making

KW - gene expression

KW - genomics risk

KW - prognosis

KW - tumor

UR - https://www.scopus.com/pages/publications/85013435790

U2 - 10.1002/jso.24561

DO - 10.1002/jso.24561

M3 - Artículo de revisión

C2 - 28211064

AN - SCOPUS:85013435790

SN - 0022-4790

VL - 115

SP - 647

EP - 662

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

IS - 6

ER -

Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays

Resumen

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto